drugset / Trial / NCT05994599

Comparative Bioavailability Study of Ethinyl Estradiol/Etonogestrel Vaginal Ring

NCT05994599

Phase 1 Completed 36 enrolled Evestra Inc.
RandomizedCrossoverSingle-blindPrevention

Summary

Single Dose Crossover Comparative Bioavailability Study of Ethinyl Estradiol/Etonogestrel Vaginal Ring (Delivering 0.015 mg/0.12 mg Per Day) Worn for 21 Days in Healthy Female Subjects

Timeline

Start
2023-07-29
Primary completion
2023-12-11
Completion
2023-12-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Etonogestrel Unknown 0.12 mg Other
Subject ethinyl estradiol Small molecule 0.015 mg Other

Indications

No indication recorded.